Interaction between mesenchymal stem cells and B-cells

International Journal of Molecular Sciences

Volumn 17, Issue 5, 2016, Pages

  Fan, Linxiao ^a   Hu, Chenxia ^a   Chen, Jiajia ^a   Cen, Panpan ^a   Wang, Jie ^a   Li, Lanjuan ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

B cell; Cytokine; Graft versus host disease; Immune regulation; Immune suppression; Mesenchymal stem cell; Plasma cell; Systemic lupus erythematous; T cell

Indexed keywords

B LYMPHOCYTE INDUCED MATURATION PROTEIN 1; CCAAT ENHANCER BINDING PROTEIN; COMPLEMENT COMPONENT C3; ECALECTIN; EPIDERMAL GROWTH FACTOR RECEPTOR; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 4; INTERLEUKIN 8; INTERSTITIAL COLLAGENASE; MITOGEN ACTIVATED PROTEIN KINASE P38; MONOCYTE CHEMOTACTIC PROTEIN 1; PROGRAMMED DEATH 1 LIGAND 1; PROSTAGLANDIN E2; PROTEIN KINASE B; STRESS ACTIVATED PROTEIN KINASE; STROMAL CELL DERIVED FACTOR 1; TOLL LIKE RECEPTOR 4; TRANSCRIPTION FACTOR PAX5; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; ZINC FINGER PROTEIN; CYTOKINE; LIPOPOLYSACCHARIDE;

B LYMPHOCYTE; BONE MARROW DERIVED MESENCHYMAL STEM CELL; CELL DIFFERENTIATION; CELL INTERACTION; CELL PROLIFERATION; DOWN REGULATION; HEMATOPOIETIC STEM CELL; HUMAN; IMMUNOREGULATION; MESENCHYMAL STEM CELL; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; UPREGULATION; ANIMAL; GRAFT VERSUS HOST REACTION; IMMUNOLOGY; MESENCHYMAL STROMA CELL; METABOLISM; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANIMALS; B-LYMPHOCYTES; CYTOKINES; GRAFT VS HOST DISEASE; HUMANS; LIPOPOLYSACCHARIDES; LUPUS ERYTHEMATOSUS, SYSTEMIC; MESENCHYMAL STROMAL CELLS; SIGNAL TRANSDUCTION;

EID: 84965161090     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms17050650     Document Type: Review

References (103)

1. Barry, F.P.; Murphy, J.M.; English, K.; Mahon, B.P. Immunogenicity of adult mesenchymal stem cells: Lessons from the fetal allograft. Stem Cells Dev. 2005, 14, 252-265. [CrossRef] [PubMed]
2. Horwitz, E.M.; Le Blanc, K.; Dominici, M.; Mueller, I.; Slaper-Cortenbach, I.; Marini, F.C.; Deans, R.J.; Krause, D.S.; Keating, A. International Society for Cellular Therapy. Clarification of the nomenclature for MSC: The international society for cellular therapy position statement. Cytotherapy 2005, 7, 393-395. [CrossRef] [PubMed]
3. Silva Meirelles, L.D.; Caplan, A.I.; Nardi, N.B. In search of the in vivo identity of mesenchymal stem cells. Stem Cells 2008, 26, 2287-2299. [CrossRef] [PubMed]
4. Bassi, Ê.J.; Moraes-Vieira, P.M.; Moreira-Sá, C.S.; Almeida, D.C.; Vieira, L.M.; Cunha, C.S.; Hiyane, M.I.; Basso, A.S.; Pacheco-Silva, A.; Câmara, N.O. Immune regulatory properties of allogeneic adipose-derived mesenchymal stem cells in the treatment of experimental autoimmune diabetes. Diabetes 2012, 61, 2534-2545. [CrossRef] [PubMed]
5. Meierhenry, J.A.; Ryzhuk, V.; Miguelino, M.G.; Lankford, L.; Powell, J.S.; Farmer, D.; Wang, A. Placenta as a source of stem cells for regenerative medicine. Curr. Pathobiol. Rep. 2015, 3, 9-16. [CrossRef]
6. Wang, D.; Huang, S.; Yuan, X.; Liang, J.; Xu, R.; Yao, G.; Feng, X.; Sun, L. The regulation of the Treg/Th17 balance by mesenchymal stem cells in human systemic lupus erythematosus. Cell. Mol. Immunol. 2015. [CrossRef] [PubMed]
7. Mou, X.Z.; Lin, J.; Chen, J.Y.; Li, Y.F.; Wu, X.X.; Xiang, B.Y.; Li, C.Y.; Ma, J.M.; Xiang, C. Menstrual blood-derived mesenchymal stem cells differentiate into functional hepatocyte-like cells. J. Zhejiang Univ. B 2013, 14, 961-972. [CrossRef] [PubMed]
8. Zhang, Q.Z.; Shi, S.H.; Liu, Y.; Uyanne, J.; Shi, Y.F.; Shi, S.T.; Anh, D. Mesenchymal stem cells derived from human gingiva are capable of immunomodulatory functions and ameliorate inflammation-related tissue destruction in experimental colitis. J. Immunol. 2009, 183, 7787-7798. [CrossRef] [PubMed]
9. Pittenger, M.F.; Mackay, A.M.; Beck, S.C.; Jaiswal, R.K.; Douglas, R.; Mosca, J.D.; Moorman, M.A.; Simonetti, D.W.; Craig, S.; Marshak, D.R. Multilineage potential of adult human mesenchymal stem cells. Science 1999, 284, 143-147. [CrossRef] [PubMed]
10. Soufiane, G.; Pène, J.; Torcy-Moquet, G.; Jorgensen, C.; Yssel, H. Correction: Mesenchymal stem cells inhibit human th17 cell differentiation and function and induce a T regulatory cell phenotype. J. Immunol. 2010, 185, 302-312. [CrossRef]
11. Spaggiari, G.M.; Capobianco, A.; Abdelrazik, H.; Becchetti, F.; Mingari, M.C.; Moretta, L. Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: Role of indoleamine 2,3-dioxygenase and prostaglandin E2. Blood 2008, 111, S47. [CrossRef]
12. Karen, E.; Barry, F.P.; Mahon, B.P. Murine mesenchymal stem cells suppress dendritic cell migration, maturation and antigen presentation. Immunol. Lett. 2008, 115, 50-58.
13. Németh, K.; Leelahavanichkul, A.; Yuen, P.S.T.; Mayer, B.; Parmelee, A.; Doi, K.; Robey, P.G.; Leelahavanichkul, K.; Koller, H.B.; Brown, M.J., et al. Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nat. Med. 2009, 15, 42-49. [CrossRef] [PubMed]
14. Blanc, K.L.; Frassoni, F.; Ball, L.; Locatelli, F.; Roelofs, H.; Lewis, L.; Lanino, E.; Sunberg, B.; Bernardo, M.E.; Remberger, M., et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: A phase II study. Lancet 2008, 371, 1579-1586. [CrossRef]
15. Ryang Hwa, L.; Jeong, S.M.; Reger, R.L.; Spees, J.L.; Pulin, A.A.; Olson, S.D.; Prockop, D.J. Multipotent stromal cells from human marrow home to and promote repair of pancreatic islets and renal glomeruli in diabetic NOD/scid mice. Proc. Natl. Acad. Sci. USA 2006, 103, 17438-17443.
16. Cedric, M.; Luciano, P.; Giulio, B.; Joelle, D.; Francesco, B.; Isabelle, B. Clinical-grade mesenchymal stromal cells produced under various good manufacturing practice processes differ in their immunomodulatory properties: standardization of immune quality controls. Stem Cells Dev. 2013, 22, 1789-1801.
17. Asari, S.; Itakura, S.; Ferreri, K.; Liu, C.P.; Kuroda, Y.; Kandeel, F.; Mullen, Y. Mesenchymal stem cells suppress B-cell terminal differentiation. Exp. Hematol. 2009, 37, 604-615. [CrossRef] [PubMed]
18. Ji, Y.R.; Yang, Z.X.; Han, Z.B.; Meng, L.; Liang, L.; Feng, X.M.; Yang, S.G.; Chi, Y.; Chen, D.D.; Wang, Y.W., et al. Mesenchymal stem cells support proliferation and terminal differentiation of B cells. Cell. Physiol. Biochem. Int. J. Exp. Cell Physiol. Biochem. Pharmacol. 2012, 30, 1526-1537. [CrossRef] [PubMed]
19. 2+-related signaling events influence TLR9-induced IL-10 secretion in human B cells. Eur. J. Immunol. 2014, 44, 1285-1298. [CrossRef] [PubMed]
20. Hardy, R.R.H.; Hayakawa, K. B cell development pathways. Annu. Rev. Immunol. 2001, 19, 595-621. [CrossRef] [PubMed]
21. Kondo, M. Lymphoid and myeloid lineage commitment in multipotent hematopoietic progenitors. Immunol. Rev. 2010, 238, 37-46. [CrossRef] [PubMed]
22. Kazu, K.; Lai, A.Y.; Chia-Lin, H.; Kondo, M. IL-7 receptor signaling is necessary for stage transition in adult B cell development through up-regulation of EBF. J. Exp. Med. 2005, 201, 1197-1203.
23. Muraguchi, A.; Hirano, T.; Tang, B.; Matsuda, T.; Horii, Y.; Nakajima, K.; Kishimoto, T. The essential role of B cell stimulatory factor 2 (BSF-2/IL-6) for the terminal differentiation of B cells. J. Exp. Med. 1988, 167, 332-344. [CrossRef] [PubMed]
24. Pène, J.; Rousset, F.; Brière, F.; Chrétien, I.; Paliard, X.; Banchereau, J.; Spits, H.; de Vries, J.E. IgE production by normal human B cells induced by alloreactive T cell clones is mediated by IL-4 and suppressed by IFN-gamma. J. Immunol. 1988, 141, 1218-1224. [PubMed]
25. Smith, K.M.; Pottage, L.; Thomas, E.R.; Leishman, A.J.; Doig, T.N.; Xu, D.; Liew, F.Y.; Garside, P. Th1 and Th2 CD4+ T cells provide help for B cell clonal expansion and antibody synthesis in a similar manner in vivo. J. Immunol. 2000, 165, 3136-3144. [CrossRef] [PubMed]
26. Craxton, A.; Magaletti, D.; Ryan, E.J.; Clark, E.A. Macrophage- and dendritic cell—dependent regulation of human B-cell proliferation requires the TNF family ligand BAFF. Blood 2003, 101, 4464-4471. [CrossRef] [PubMed]
27. Najimi, M.; Khuu, D.N.; Lysy, P.A.; Jazouli, N.; Abarca, J.; Sempoux, C.; Sokal, E.M. Adult-derived human liver mesenchymal-like cells as a potential progenitor reservoir of hepatocytes? Cell Transplant. 2007, 16, 717-728. [CrossRef] [PubMed]
28. El-Kehdy, H.; Pourcher, G.; Zhang, W.; Hamidouche, Z.; Mainot, S.G.; Sokal, E.; Charbord, P.; Najimi, M.; Kupperschmitt, A.D. Hepatocytic differentiation potential of human fetal liver mesenchymal stem cells: In vitro and in vivo evaluation. Stem Cell Int. 2016, 2016, 1-12. [CrossRef] [PubMed]
29. Yanaba, K.; Bouaziz, J.D.; Matsushita, T.; Magro, C.M.; Clair, E.W.; Tedder, T.F. B-lymphocyte contributions to human autoimmune disease. Immunol. Rev. 2008, 223, 284-299. [CrossRef] [PubMed]
30. Akiyama, K.; Chen, C.; Wang, D.; Xu, X.; Qu, C.; Yamaza, T.; Cai, T.; Chen, W.; Sun, L.; Shi, S. Mesenchymal-stem-cell-induced immunoregulation involves FAS-ligand-/FAS-mediated T cell apoptosis. Cell Stem Cell 2012, 10, 544-555. [CrossRef] [PubMed]
31. Madec, A.M.; Mallone, R.G. Mesenchymal stem cells protect NOD mice from diabetes by inducing regulatory T cells. Diabetologia 2009, 52, 1391-1399. [CrossRef] [PubMed]
32. Ren, G.; Zhang, L.; Zhao, X.; Xu, G.; Zhang, Y.; Roberts, A.; Zhao, C.; Shi, Y. Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell 2008, 2, 141-150. [CrossRef] [PubMed]
33. Ryan, J.M.; Barry, F.; Murphy, J.M.; Mahon, B.P. Interferon- does not break, but promotes the immunosuppressive capacity of adult human mesenchymal stem cells. Clin. Exp. Immunol. 2007, 149, 353-363. [CrossRef] [PubMed]
34. Syuichi, K.; Yoshifumi, T. RP105-negative B cells in systemic lupus erythematosus. Clin. Dev. Immunol. 2012, 2012, 259186.
35. Che, N.; Li, X.; Zhang, L.; Liu, R.; Chen, H.; Gao, X.; Shi, S.; Chen, W.; Sun, L. Impaired B cell inhibition by lupus bone marrow mesenchymal stem cells is caused by reduced CCL2 expression. J. Immunol. 2014, 193, 5306-5314. [CrossRef] [PubMed]
36. Feng, X.; Che, N.; Liu, Y.; Chen, H.; Wang, D.; Li, X.; Chen, W.; Ma, X.; Hua, B.; Gao, X., et al. Restored immunosuppressive effect of mesenchymal stem cells on b cells after olfactory 1/early b cell factor-associated zinc-finger protein down-regulation in patients with systemic lupus erythematosus. Arthritis Rheumatol. 2014, 66, 3413-3423. [CrossRef] [PubMed]
37. Yoshioka, S.; Miura, Y.; Yao, H.; Satake, S.; Hayashi, Y.; Tamura, A.; Hishita, T.; Ichinohe, T.; Hirai, H.; Takaor-Kondo, A., et al. CCAAT/enhancer-binding protein _ expressed by bone marrow mesenchymal stromal cells regulates early B-cell lymphopoiesis. Stem Cells 2014, 32, 730-740. [CrossRef] [PubMed]
38. Wang, H.Y.; Chen, T.; Ding, T.L.; Zhu, P.; Xu, X.P.; Yu, L.; Xie, Y. Adipogenic differentiation alters the immunoregulatory property of mesenchymal stem cells through BAFF secretion. Hematology 2011, 16, 313-323. [CrossRef] [PubMed]
39. Yan, H.; Wu, M.; Yuan, Y.; Wang, Z.Z.; Jiang, H.; Chen, T. Priming of Toll-like receptor 4 pathway in mesenchymal stem cells increases expression of B cell activating factor. Biochem. Biophys. Res. Commun. 2014, 448, 212-217. [CrossRef] [PubMed]
40. Nan, C.; Xia, L.; Zhou, S.; Liu, R.; Shi, D.; Lu, L.; Sun, L. Umbilical cord mesenchymal stem cells suppress B-cell proliferation and differentiation. Cell. Immunol. 2012, 274, 46-53.
41. Charalampos, P.; Maria-Christina, K.; Mirjam, K.; Christina, K.; Pavlos, K.; Kalliopi, A.; Gerassimos, A.P.; Helen, A.P. Study of the quantitative, functional, cytogenetic, and immunoregulatory properties of bone marrow mesenchymal stem cells in patients with B-cell chronic lymphocytic leukemia. Stem Cells Dev. 2013, 22, 1329-1341.
42. Lee, D.; Yi, T.; Lee, H.; Kim, S.; Park, S.; Jeon, M.; Song, S. Mesenchymal stem cells infected with Mycoplasma arginini secrete complement C3 to regulate immunoglobulin production in b lymphocytes. Cell Death Dis. 2014, 5, e1192. [CrossRef] [PubMed]
43. Su, W.; Wan, Q.; Huang, J.; Han, L.; Chen, X.; Chen, G.; Olsen, N.; Zheng, S.G.; Liang, D. Culture medium from TNF-α-stimulated mesenchymal stem cells attenuates allergic conjunctivitis through multiple antiallergic mechanisms. J. Allergy Clin. Immunol. 2015, 136, 423-432. [CrossRef] [PubMed]
44. Wang, H.; Qi, F.; Dai, X.; Tian, W.; Liu, T.; Han, H.; Zhang, B.; Li, H.; Zhang, Z.; Du, C. Requirement of B7-H1 for immune tolerance to cardiac allografts in combination therapy of mesenchymal stem cells and rapamycin. Transplant Immunol. 2014, 31, 65-74. [CrossRef] [PubMed]
45. Daniela, C.; Marina, N. Toward a B-cell signature of tolerance? Kidney Int. 2010, 78, 435-437.
46. Salinas, G.F.; Braza, F.; Brouard, S.; Tak, P.P.; Baeten, D. The role of B lymphocytes in the progression from autoimmunity to autoimmune disease. Clin. Immunol. 2013, 146, 34-45. [CrossRef] [PubMed]
47. Klinker, M.W.; Lundy, S.K. Multiple mechanisms of immune suppression by B lymphocytes. Mol. Med. 2012, 18, 123-137. [CrossRef] [PubMed]
48. Antin, J.H.; Ault, K.A.; Rappeport, J.M.; Smith, B.R. B lymphocyte reconstitution after human bone marrow transplantation. Leu-1 antigen defines a distinct population of B lymphocytes. J. Clin. Investig. 1987, 80, 325-332. [CrossRef] [PubMed]
49. Moins-Teisserenc, H.; Busson, M.; Herda, A.; Apete, S.; Peffault de Latour, R.; Robin, M.; Xhaard, A.; Toubert, A.; Socié, G. CD19+CD5+ B cells and B1-like cells following allogeneic hematopoietic stem cell transplantation. Biol. Blood Marrow Transplant. 2013, 80, 988-991. [CrossRef] [PubMed]
50. Samoˇılovich, M.P.; Pinevich, A.A.; Shashkova, O.A.; Vartanian, N.L.; Kiseleva, L.N.; Klimovich, V.B. Influence of mesenchymal stromal cells on B-cell line growth and immunoglobulin synthesis. Cell Tissue Biol. 2013, 55, 227-234. [CrossRef]
51. Rodríguez-Pardo, V.M.; Aristizabal, J.A.; Jaimes, D.; Quijano, S.M.; de los Reyes, I.; Herrera, M.V.; Solano, J.; Vernot, J.P. Mesenchymal stem cells promote leukaemic cells aberrant phenotype from B-cell acute lymphoblastic leukaemia. Hematol. Oncol. Stem Cell Ther. 2013, 6, 89-100. [CrossRef] [PubMed]
52. Peng, Y.; Chen, X.; Liu, Q.; Zhang, X.; Huang, K.; Liu, L.; Li, H.; Zhou, M.; Huang, F.; Fan, Z., et al. Mesenchymal stromal cells infusions improve refractory chronic graft versus host disease through an increase of CD5+ regulatory B cells producing interleukin 10. Leukemia 2015, 29, 636-646. [CrossRef] [PubMed]
53. Healy, M.E.; Bergin, R.; Mahon, B.P.; English, K. Mesenchymal stromal cells protect against caspase 3-mediated apoptosis of CD19+ peripheral B cells through contact-dependent upregulation of VEGF. Stem Cells Dev. 2015, 24, 2391-2402. [CrossRef] [PubMed]
54. Barrio, L.; Cuevas, V.D.; Menta, R.; Mancheño-Corvo, P.; delaRosa, O.; Dalemans, W.; Lombardo, E.; Carrasco, Y.R. Human adipose tissue-derived mesenchymal stromal cells promote B-cell motility and chemoattraction. Cytotherapy 2014, 16, 1692-1699. [CrossRef] [PubMed]
55. Corcione, A.; Benvenuto, F.; Ferretti, E.; Giunti, D.; Cappiello, V.; Cazzanti, F.; Risso, M.; Gualandi, F.; Mancardi, G.L.; Pistoia, V., et al. Human mesenchymal stem cells modulate B-cell functions. Blood 2006, 107, 367-372. [CrossRef] [PubMed]
56. Rosado, M.M.; Bernardo, M.E.; Scarsella, M.; Conforti, A.; Giorda, E.; Biagini, S.; Cascioli, S.; Rossi, F.; Guzzo, I.; Vivarelli, M. Inhibition of B-Cell proliferation and antibody production by mesenchymal stromal cells is mediated by T cells. Stem Cells Dev. 2015, 24, 93-103. [CrossRef] [PubMed]
57. Nauta, A.J.; Kruisselbrink, A.B.; Lurvink, E.; Willemze, R.; Fibbe, W.E. Mesenchymal stem cells inhibit generation and function of both CD34 +—Derived and monocyte-derived dendritic cells. J. Immunol. 2008, 177, 2080-2087. [CrossRef]
58. Hadi, V.; Karin, E.; Apostolos, B.; Margareta, S.; James, L.; Jan, L. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat. Cell Biol. 2007, 9, 654-659.
59. Jiang, X.; Zhang, Y.; Liu, B.; Zhang, S.; Wu, Y.; Yu, X.; Mao, N. Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. Blood 2005, 105, 4120-4126. [CrossRef] [PubMed]
60. Li, H.; Guo, Z.K.; Li, X.S.; Hou, C.M.; Tang, P.H.; Mao, N. Functional and phenotypic alteration of intrasplenic lymphocytes affected by mesenchymal stem cells in a murine allosplenocyte transfusion model. Cell Transplant. 2007, 16, 85-95. [CrossRef] [PubMed]
61. Rosa, S.L.; Sayegh, M.H. Frontiers immunomodulatory function of bone marrow-derived mesenchymal stem cells in experimental autoimmune type 1 diabetes. Am. J. Bioeth. 2009, 9, 3-12.
62. Ungerer, C.; Quade-Lyssy, P.; Radeke, H.H.; Henschler, R.; Königs, C.; Köhl, U.; Seifried, E.; Schüttrumpf, J. Galectin-9 is a suppressor of T and B cells and predicts the immune modulatory potential of mesenchymal stromal cell preparations. Stem Cells Dev. 2014, 23, 755-766. [CrossRef] [PubMed]
63. Ma, X.; Che, N.; Gu, Z.; Huang, J.; Wang, D.; Liang, J.; Hou, Y.; Gilkeson, G.; Lu, L.; Sun, L. Allogenic mesenchymal stem cell transplantation ameliorates nephritis in lupus mice via inhibition of B-cell activation. Cell Transplant. 2013, 22, 2279-2290. [CrossRef] [PubMed]
64. Nakagawa, T.; Hirano, T.; Nakagawa, N.; Yoshizaki, K.; Kishimoto, T. Effect of recombinant IL 2 and -IFN on proliferation and differentiation of human B cells. J. Immunol. 1985, 134, 959-966. [PubMed]
65. Franquesa, M.; Mensah, F.K.; Huizinga, R.; Strini, T.; Boon, L.; Lombardo, E.; DelaRosa, O.; Laman, J.D.; Grinyó, J.M.; Weimar, W. Human adipose tissue-derived mesenchymal stem cells abrogate plasmablast formation and induce regulatory B cells independently of T helper cells. Stem Cells 2015, 33, 880-891. [CrossRef] [PubMed]
66. English, K.; Barry, F.P.; Field-Corbett, C.P.; Mahon, B.P. IFN-γ and TNF-αdifferentially regulate immunomodulation by murine mesenchymal stem cells. Immunol. Lett. 2007, 110, 91-100. [CrossRef] [PubMed]
67. Clotilde, T.; Matias, O.; Elodie, S. Membrane vesicles as conveyors of immune responses. Nat. Rev. Immunol. 2009, 9, 581-593.
68. Camussi, G.; Deregibus, M.C.; Bruno, S.; Cantaluppi, V.; Biancone, L. Exosomes/microvesicles as a mechanism of cell-to-cell communication. Kidney Int. 2010, 78, 838-848. [CrossRef] [PubMed]
69. Budoni, M.; Fierabracci, A.; Luciano, R.; Petrini, S.; di Ciommo, V.; Muraca, M. The immunosuppressive effect of mesenchymal stromal cells on B lymphocytes is mediated by membrane vesicles. Cell Transplant. 2013, 22, 369-379. [CrossRef] [PubMed]
70. Antonella, C.; Marco, S.; Nadia, S. Microvescicles derived from mesenchymal stromal cells are not as effective as their cellular counterpart in the ability to modulate immune responses in vitro. Stem Cells Dev. 2014, 23, 2591-2599.
71. Galeh, H.E.G.; Delirezh, N.; Froushani, S.M.A.; Ahangaran, N.A. Calcitriol modulates the effects of the supernatants of bone-marrow-derived mesenchymal stem cells on neutrophil functions. Turk. J. Biol. 2014, 38, 365-370. [CrossRef]
72. Brandau, S.; Jakob, M.; Bruderek, K.; Bootz, F.; Giebel, B.; Radtke, S.; Mauel, K.; Jäger, M.; Flohé, S.B.; Lang, S. Mesenchymal stem cells augment the anti-bacterial activity of neutrophil granulocytes. PLoS ONE 2014, 9, e106903. [CrossRef] [PubMed]
73. Hsu, S.C.; Wang, L.T.; Yao, C.L.; Lai, H.Y.; Chan, K.Y.; Liu, B.S.; Chong, P.; Lee, O.K.; Chen, H.W. Mesenchymal stem cells promote neutrophil activation by inducing IL-17 production in CD4+ CD45RO+ T cells. Immunobiology 2013, 218, 90-95. [CrossRef] [PubMed]
74. Deng, W.; Chen, W.; Zhang, Z.; Huang, S.; Kong, W.; Sun, Y.; Tang, X.; Yao, G.; Feng, X.; Chen, W., et al. Mesenchymal stem cells promote CD206 expression and phagocytic activity of macrophages through IL-6 in systemic lupus erythematosus. Clin. Immunol. 2015, 161, 209-216. [CrossRef] [PubMed]
75. Mitchison, N.A.; Wedderburn, L.R. B cells in autoimmunity. Proc. Natl. Acad. Sci. USA 2000, 97, 8750-8751. [CrossRef] [PubMed]
76. Schlossman, I.L.; Myrick, S.E.; Zhuang, H.; Wang, H.; Reeves, W.H. Role of tumor necrosis factor α in bone marrow niche dysfunction of patients with systemic lupus erythematosus (SLE). Blood 2013, 122, 1036.
77. Sui, W.; Hou, X.; Che, W.; Chen, J.; Ou, M.; Xue, W.; Dai, Y. Hematopoietic and mesenchymal stem cell transplantation for severe and refractory systemic lupus erythematosus. Clin. Immunol. 2013, 148, 186-197. [CrossRef] [PubMed]
78. Erin, C.; Fei, G.; Maosong, Q.; Ivan, M.; Phillip, R.; Sun, L.; Gilkeson, G.S. Differential efficacy of human mesenchymal stem cells based on source of origin. J. Immunol. 2014, 193, 4381-4390.
79. Gu, F.; Molano, I.; Ruiz, P.; Sun, L.; Gilkeson, G.S. Differential effect of allogeneic versus syngeneic mesenchymal stem cell transplantation in MRL/lpr and (NZB/NZW)F1 mice. Clin. Immunol. 2012, 145, 142-152. [CrossRef] [PubMed]
80. Park, M.J.; Kwok, S.K.; Lee, S.H.; Cho, M.L. Adipose tissue-derived mesenchymal stem cells induce expansion of Interleukin-10 producing regulatory B cells and ameliorate autoimmunity in a murine model of systemic lupus erythematosus. Cell Transplant. 2015, 24, 2367-2377. [CrossRef] [PubMed]
81. Sun, L.Y.; Akiyama, K.; Zhang, H.; Yamaza, T.; Hou, Y.; Zhao, S.; Xu, T.; Le, A.; Shi, S. Mesenchymal stem cell transplantation reverses multiorgan dysfunction in systemic lupus erythematosus mice and humans. Stem Cells 2009, 27, 1421-1432. [CrossRef] [PubMed]
82. Liang, J.; Zhang, H.; Hua, B.; Wang, H.; Lu, L.; Shi, S.; Hou, Y.; Zeng, X.; Gilkeson, G.S.; Sun, L. Allogenic mesenchymal stem cells transplantation in refractory systemic lupus erythematosus: A pilot clinical study. Ann. Rheum. Dis. 2010, 69, 1423-1429. [CrossRef] [PubMed]
83. Bhatia, S.; Francisco, L.; Carter, A.; Liu, Y.; Grant, M. Late mortality after allogeneic hematopoietic cell transplantation and functional status of long-term survivors: Report from the bone marrow transplant survivor study. Blood 2007, 110, 3784-3792. [CrossRef] [PubMed]
84. Blazar, B.R.; Murphy, W.J.; Mehrdad, A. Advances in graft-versus-host disease biology and therapy. Nat. Rev. Immunol. 2012, 12, 443-458. [CrossRef] [PubMed]
85. Shimabukuro-Vornhagen, A.; Hallek, M.J.; Storb, R.F.; von Bergwelt-Baildon, M.S. The role of B cells in the pathogenesis of graft-versus-host disease. Blood 2009, 114, 4919-4927. [CrossRef] [PubMed]
86. Sarantopoulos, S.; Stevenson, K.E.; Kim, H.T.; Cutler, C.S.; Bhuiya, N.; Schowalter, M. Altered B cell homeostasis and excess BAFF in human chronic graft versus host disease. Blood 2009, 113, 3865-3874. [CrossRef] [PubMed]
87. Ratanatharathorn, V.; Carson, E.; Reynolds, C.; Ayash, L.J.; Levine, J.; Yanik, G.; Silver, S.M.; Ferrara, J.L.; Uberti, J.P. Anti-CD20 chimeric monoclonal antibody treatment of refractory immune-mediated thrombocytopenia in a patient with chronic graft-versus-host disease. Ann. Intern. Med. 2000, 133, 275-279. [CrossRef] [PubMed]
88. Yoshizaki, A.; Miyagaki, T.; DiLillo, D.J.; Matsushita, T.; Horikawa, M.; Kountikov, E.I.; Spolski, R.; Poe, J.C.; Leonard, W.J.; Tedder, T.F. Regulatory B cells control T-cell autoimmunity through IL-21-dependent cognate interactions. Nature 2012, 491, 264-268. [CrossRef] [PubMed]
89. Joo, S.Y.; Cho, K.A.; Jung, Y.J.; Kim, H.S.; Park, S.Y.; Choi, Y.B.; Hong, K.M.; Woo, S.Y.; Seoh, J.Y.; Cho, S.J., et al. Mesenchymal stromal cells inhibit graft-versus-host disease of mice in a dose-dependent manner. Cytotherapy 2010, 12, 361-370. [CrossRef] [PubMed]
90. Tisato, V.; Naresh, K.; Girdlestone, J.; Navarrete, C.; Dazzi, F. Mesenchymal stem cells of cord blood origin are effective at preventing but not treating graft-versus-host disease. Leukemia 2007, 21, 1992-1999. [CrossRef] [PubMed]
91. Chung, N.G.; Jeong, D.C.; Park, S.J.; Choi, B.O.; Cho, B.; Kim, H.K.; Chun, C.S.; Won, J.H.; Han, C.W. Cotransplantation of marrow stromal cells may prevent lethal graft-versus-host disease in major histocompatibility complex mismatched murine hematopoietic stem cell transplantation. Int. J. Hematol. 2004, 80, 370-376. [CrossRef] [PubMed]
92. Sudres, M.; Norol, F.; Trenado, A.; Grégoire, S.; Charlotte, F.; Levacher, B.; Lataillade, J.J.; Bourin, P.; Holy, X.; Vernant, J.P., et al. Bone marrow mesenchymal stem cells suppress lymphocyte proliferation in vitro but fail to prevent graft-versus-host disease in mice. J. Immunol. 2006, 176, 7761-7767. [CrossRef] [PubMed]
93. Ringdén, O.; Uzunel, M.; Rasmusson, I.; Remberger, M.; Sundberg, B.; Lönnies, H.; Marschall, H.U.; Dlugosz, A.; Szakos, A.; Hassan, Z. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation 2006, 81, 1390-1397. [CrossRef] [PubMed]
94. Richard, H.; Marian, S.; Kathryn, S.; Duncan, P.; Julian, C.; Matthew, W.; Michael, P.; Paul, C. Mesenchymal stromal cell therapy for steroid-refractory acute and chronic graft versus host disease: A phase 1 study. Int. J. Hematol. 2012, 95, 182-188.
95. Pérez-Simon, J.A.; López-Villar, O.; Andreu, E.J.; Rifon, J.; Muntion, S.; Campelo, M.D.; Guijo, F.M.; Martinez, C.; Valcarcel, D.; Canizo, C. Mesenchymal stem cells expanded in vitro with human serum for the treatment of acute and chronic graft-versus-host disease: Results of a phase I/II clinical trial. Haematologica 2011, 96, 1072-1076. [CrossRef] [PubMed]
96. Peng, Y.; Chen, X.; Liu, Q.; Xu, D.; Zheng, H.; Liu, L.; Liu, Q.; Liu, M.; Fan, Z.; Sun, J., et al. Alteration of naïve and memory B-cell subset in chronic graft-versus-host disease patients after treatment with mesenchymal stromal cells. Stem Cells Transl. Med. 2014, 3, 1023-1031. [CrossRef] [PubMed]
97. Neurath, M.F.; Finotto, S.; Glimcher, L.H. The role of Th1/Th2 polarization in mucosal immunity. Nat. Med. 2002, 8, 567-573. [CrossRef] [PubMed]
98. Barros, M.H.; Hauck, F.; Dreyer, J.H.; Kempkes, B.; Niedobitek, G. Macrophage polarisation: An immunohistochemical approach for identifying M1 and M2 macrophages. PLoS ONE 2013, 8, e80908. [CrossRef] [PubMed]
99. Waterman, R.S.; Tomchuck, S.L.; Henkle, S.L.; Betancourt, A.M. A new mesenchymal stem cell (MSC) paradigm: Polarization into a pro-inflammatory MSC1 or an Immunosuppressive MSC2 phenotype. PLoS ONE 2010, 5, e10088. [CrossRef] [PubMed]
100. Tomchuck, S.L.; Zwezdaryk, K.J.; Coffelt, S.B.; Waterman, R.S.; Danka, E.S.; Scandurro, A.B. Toll-like receptors on human mesenchymal stem cells drive their migration and immunomodulating responses. Stem Cells 2008, 26, 99-107. [CrossRef] [PubMed]
101. Duffy, M.M.; Pindjakova, J.; Hanley, S.A.; McCarthy, C.; Weidhofer, G.A.; Sweeney, E.M.; English, K.; Shaw, G.; Murphy, J.M.; Barry, F.P., et al. Mesenchymal stem cell inhibition of T-helper 17 cell-differentiation is triggered by cell-cell contact and mediated by prostaglandin E2 via the EP4 receptor. Eur. J. Immunol. 2011, 41, 2840-2851. [CrossRef] [PubMed]
102. English, K.; Ryan, J.M.; Tobin, L.; Murphy, M.J.; Barry, F.P.; Mahon, B.P. Cell contact, prostaglandin E(2) and transforming growth factor beta 1 play non-redundant roles in human mesenchymal stem cell induction of CD4+CD25(High) forkhead box P3+ regulatory T cells. Clin. Exp. Immunol. 2009, 156, 149-160. [CrossRef] [PubMed]
103. Rasmusson, I.; Le-Blanc, K.B.; Ringden, O. Mesenchymal stem cells stimulate antibody secretion in human B cells. Scand. J. Immunol. 2007, 65, 336-343. [CrossRef] [PubMed]